Patrick Dolezal
LifeSci Capital
Recent Quotes
"DRRX plans to respond to a complete response letter for Posimir."
—
Patrick Dolezal, LifeSci Capital
(2/27/19)
more >
"DRRX will move its alcoholic hepatitis program to Dr. Craig McClain."
—
Patrick Dolezal, LifeSci Capital
(1/7/19)
more >
"For DRRX's trial of DUR-928 for PSC, data are anticipated in 2018."
—
Patrick Dolezal, LifeSci Capital
(7/30/18)
more >
"DRRX began dosing of a DUR-928 Phase 2a trial in alcoholic hepatitis."
—
Patrick Dolezal, LifeSci Capital
(4/25/18)
more >
"DRRX began dosing of a DUR-928 Phase 2a trial in alcoholic hepatitis."
—
Patrick Dolezal, LifeSci Capital
(4/25/18)
more >
"DRRX has initiated dosing in a Phase IIatrial for DUR-928 in the treatment of primary sclerosing cholangitis."
—
Patrick Dolezal, LifeSci Capital
(2/27/18)
more >
"DRRX announced the FDA has accepted the NDA for Invidior's RBP-2000."
—
Patrick Dolezal, LifeSci Capital
(12/13/17)
more >
"DRRX intends to initiate a Phase 2 study of oral DUR-928 in Q4/17."
—
Patrick Dolezal, LifeSci Capital
(10/20/17)
more >
